Multiple myeloma
What is Multiple myeloma?
Multiple myeloma is a type of blood cancer that begins in plasma cells. Plasma cells are white blood cells that live in your bone marrow and make antibodies to fight infections. When these cells become cancerous, they multiply out of control and crowd out healthy blood cells.
As myeloma cells grow, they produce abnormal proteins that build up in your blood and urine. These proteins can damage your kidneys, weaken your bones, and interfere with your immune system. The condition typically affects people over age 60, though it can occur at younger ages.
Multiple myeloma is called a plasma cell disorder or plasma cell dyscrasia. It develops slowly in most people. Some patients live with a precursor condition called monoclonal gammopathy of undetermined significance, or MGUS, for years before myeloma develops. Early detection through blood testing can help identify abnormal protein levels before symptoms appear.
Symptoms
- Bone pain, especially in the spine, chest, or hips
- Weakness and fatigue that does not improve with rest
- Frequent infections like pneumonia or sinus infections
- Unexplained weight loss over several weeks or months
- Excessive thirst and frequent urination
- Nausea, constipation, or loss of appetite
- Confusion or mental fogginess
- Numbness or weakness in the legs
- Bone fractures from minor injuries or falls
- Abnormal bleeding or easy bruising
Many people with early multiple myeloma have no symptoms at all. The condition is sometimes discovered when routine blood work shows abnormal protein levels or other changes. Symptoms usually appear gradually as the disease progresses and cancer cells spread through the bone marrow.
Concerned about Multiple myeloma? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Multiple myeloma happens when plasma cells in your bone marrow develop genetic mutations. These mutations cause the cells to grow and divide rapidly instead of dying off at a normal rate. Scientists do not know exactly what triggers these genetic changes, but several risk factors increase your likelihood of developing the condition. Age is the biggest risk factor, with most cases occurring after age 65. Men develop multiple myeloma slightly more often than women. African Americans have about twice the risk compared to white Americans.
Having MGUS, a condition where abnormal proteins appear in blood without other symptoms, raises your risk significantly. About 1 in 100 people with MGUS develop multiple myeloma each year. Family history also plays a role, as people with a close relative who has myeloma face higher risk. Exposure to radiation, certain chemicals like pesticides or benzene, and obesity may contribute to risk. However, most people with these risk factors never develop the condition, and many patients have no clear risk factors at all.
How it's diagnosed
Doctors diagnose multiple myeloma using a combination of blood tests, urine tests, imaging studies, and bone marrow examination. Blood work is often the first step and can reveal important clues. A total protein test measures the amount of protein in your blood. High levels may indicate that abnormal plasma cells are producing too much protein. Additional blood tests check for specific myeloma proteins, anemia, kidney function, and calcium levels. Rite Aid offers blood testing that includes total protein measurement, which can help identify potential concerns early.
If blood work suggests multiple myeloma, your doctor will order specialized tests. These include serum protein electrophoresis to identify abnormal proteins, free light chain tests, and beta-2 microglobulin measurements. A bone marrow biopsy confirms the diagnosis by showing the percentage of plasma cells in your marrow. Imaging tests like X-rays, MRI, CT scans, or PET scans check for bone damage. Early detection through regular blood testing at Quest Diagnostics locations can catch changes before symptoms develop.
Treatment options
- Targeted therapy drugs that attack specific proteins in myeloma cells
- Immunotherapy medications that help your immune system recognize and kill cancer cells
- Chemotherapy to destroy rapidly dividing cells
- Corticosteroids to reduce inflammation and help kill myeloma cells
- Stem cell transplant to replace diseased bone marrow with healthy cells
- Radiation therapy for bone pain or to treat tumors pressing on the spine
- Bisphosphonate medications to strengthen bones and prevent fractures
- Pain management with medications and physical therapy
- High protein diet to maintain muscle mass and support healing
- Regular exercise to maintain bone density and reduce fatigue
- Staying hydrated to protect kidney function
- Infection prevention through vaccines and avoiding sick contacts
Concerned about Multiple myeloma? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
The first signs often include persistent bone pain, especially in the back or ribs, and unexplained fatigue. Many people also experience frequent infections because myeloma weakens the immune system. Some people have no early symptoms and discover the condition through routine blood work showing abnormal protein levels.
Yes, blood tests are essential for detecting multiple myeloma. A total protein test can show elevated protein levels that suggest abnormal plasma cell activity. Doctors follow up with specialized tests like protein electrophoresis and free light chain assays to confirm the diagnosis and measure disease severity.
Multiple myeloma is not currently curable, but it is highly treatable. Many people live for years with the condition using modern therapies. Treatments can put the disease into remission, meaning cancer cells are undetectable or stable for long periods. Ongoing research continues to improve survival rates and quality of life.
Cancerous plasma cells produce abnormal antibodies and protein fragments in large amounts. These proteins, called monoclonal proteins or M proteins, build up in your blood and urine. Normal plasma cells make a variety of different antibodies, but myeloma cells all produce the same abnormal protein, causing total protein levels to rise.
People with MGUS should have blood work every 6 to 12 months to watch for progression to myeloma. If you have a family history or other risk factors, talk to your doctor about annual screening. Regular monitoring helps catch changes early when treatment is most effective.
MGUS is a precursor condition where abnormal proteins appear in blood but cause no symptoms or organ damage. Multiple myeloma occurs when abnormal plasma cells grow aggressively and damage bones, kidneys, or blood counts. About 1% of people with MGUS develop myeloma each year, so monitoring is important.
Lifestyle changes support overall health and treatment effectiveness but cannot cure myeloma. Eating a high protein diet helps maintain strength and supports healing. Regular gentle exercise preserves bone density and reduces fatigue. Staying well hydrated protects your kidneys from protein damage.
Untreated multiple myeloma leads to severe bone damage, fractures, and crippling pain. It can cause kidney failure from protein buildup and life-threatening infections from immune system suppression. Severe anemia develops as cancer cells crowd out red blood cell production. Early treatment prevents these complications and extends survival significantly.
Survival varies widely based on disease stage, age, and overall health when diagnosed. The median survival is now over 10 years with modern treatments, compared to just 3 years two decades ago. Some people live 15 to 20 years or longer. Younger patients and those diagnosed early generally have better outcomes.
Yes, doctors use the International Staging System to classify myeloma into three stages based on blood test results. Stage 1 has the best prognosis with lower levels of beta-2 microglobulin and normal albumin. Stage 3 indicates more advanced disease with higher protein markers and often requires more aggressive treatment. Staging helps guide treatment decisions and predict outcomes.